专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012018767A2 ANTIBODIES DIRECTED AGAINST IL-17 审中-公开
标题翻译：针对IL-17的抗体
公开(公告)号：WO2012018767A2
公开(公告)日：2012-02-09
申请号：PCT/US2011046201
申请日：2011-08-02
申请人： ANAPTYSBIO INC , HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
发明人： HORLICK ROBERT , KING DAVID , BOWERS PETER , DALTON JENNIFER , WU BETTY , ROBERTS TRACI , ZHANG XUE , ALTOBELL III LAURENCE
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： The invention relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The invention also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.
摘要翻译：本发明涉及分离的IL-17结合剂，其包含包含SEQ ID NO：1的免疫球蛋白重链多肽和任选的包含SEQ ID NO：23的免疫球蛋白轻链多肽，不同之处在于SEQ ID NO：1的一个或多个特异性残基 NO：1和SEQ ID NO：23被不同的残基取代。本发明还提供了使用IL-17结合剂治疗IL-17介导的疾病的载体，组合物和方法。

2. 发明申请

WO2014172448A3 ANTIBODIES DIRECTED AGAINST ACTIVIN RECEPTOR TYPE II (ACTRII) 审中-公开
标题翻译：针对II型活化受体的抗体（ACTRII）
公开(公告)号：WO2014172448A3
公开(公告)日：2015-01-08
申请号：PCT/US2014034344
申请日：2014-04-16
申请人： ANAPTYSBIO INC
发明人： VERDINO PETRA , BOWERS PETER , KING DAVID
IPC分类号： A61K39/395 , C12N15/00
CPC分类号： C07K16/2863 , C07K2317/76
摘要： The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to an activin receptor type II (ActRII) protein (e.g., either or both of ActRIIA and/or ActRIIB). The invention provides an ActRII-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the ActRII-binding agent to treat an ActRII-mediated disease.
摘要翻译：本发明涉及分离的免疫球蛋白重链多肽和分离的免疫球蛋白轻链多肽，其结合活化素受体II型（ActRII）蛋白（例如ActRIIA和/或ActRIIB中的任一者或两者）。本发明提供了包含上述免疫球蛋白重链多肽和免疫球蛋白轻链多肽的ActRII结合剂。本发明还提供使用ActRII-结合剂治疗ActRII介导的疾病的相关载体，组合物和方法。

3. 发明申请

WO2004039830A3 BIOACTIVATION OF PARTICLES 审中-公开
标题翻译：颗粒的生物活性
公开(公告)号：WO2004039830A3
公开(公告)日：2005-02-10
申请号：PCT/US0314401
申请日：2003-05-07
申请人： UNIV CALIFORNIA , PINAUD FABIEN , KING DAVID , WEISS SHIMON
发明人： PINAUD FABIEN , KING DAVID , WEISS SHIMON
IPC分类号： A61K38/00 , A61K47/48
CPC分类号： B82Y30/00 , A61K49/0056 , A61K49/0067 , B82Y5/00 , B82Y10/00 , Y10T428/2982
摘要： Particles are bioactivated by attaching bioactivation peptides to the particle surface. The bioactivation peptides are peptide-based compounds that impart one or more biologically important functions to the particles. Each bioactivation peptide includes a molecular or surface recognition part that binds with the surface of the particle and one or more functional parts. The surface recognition part includes an amino-end and a carboxy-end and is composed of one or more hydrophobic spacers and one or more binding clusters. The functional part(s) is attached to the surface recognition part at the amino-end and/or said carboxy-end.
摘要翻译：通过将生物活性肽连接到颗粒表面来生物活化颗粒。生物活化肽是赋予颗粒一个或多个生物重要功能的基于肽的化合物。每个生物活化肽包括与颗粒的表面和一个或多个功能部分结合的分子或表面识别部分。表面识别部分包括氨基末端和羧基末端，并且由一个或多个疏水间隔物和一个或多个结合簇构成。功能部分在氨基末端和/或所述羧基末端连接到表面识别部分。

4. 发明申请

WO03049704A3 ANTIBODIES TO TREAT CANCER 审中-公开
标题翻译：抗癌治疗癌症
公开(公告)号：WO03049704A3
公开(公告)日：2003-09-04
申请号：PCT/US0239811
申请日：2002-12-11
申请人： UNIV MASSACHUSETTS , CORIXA CORP , FANGER GARY R , FANGER NEIL , KING DAVID , RETTER MARC W , ROCK KENNETH L
发明人： FANGER GARY R , FANGER NEIL , KING DAVID , RETTER MARC W , ROCK KENNETH L
IPC分类号： C07K16/30 , C07H21/04 , A61K39/395 , C07K16/00
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/732
摘要： Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.
摘要翻译：公开了用于治疗癌症，特别是黑素瘤，骨髓瘤，小细胞肺癌，胸腺淋巴瘤，T细胞淋巴瘤，B细胞淋巴瘤，骨肉瘤和急性T细胞白血病的组合物和方法。说明性的组合物包括一种或多种抗神经节苷脂抗体和编码这种抗神经节苷脂抗体的多核苷酸。这些抗体可以是例如仓鼠抗体，嵌合人类/仓鼠抗体或人源化抗体。所公开的组合物可用于例如治疗癌症，并可用于诱导癌细胞凋亡。

5. 发明申请

WO2008058093A3 CONTENT MANAGEMENT SYSTEM 审中-公开
标题翻译：内容管理系统
公开(公告)号：WO2008058093A3
公开(公告)日：2008-07-24
申请号：PCT/US2007083677
申请日：2007-11-05
申请人： GOOGLE INC , CHASTAGNOL FRANCK , ZHAO JIANLIANG , CHEN RUI , GOOD MATTHEW , SU YI-LING , WAID FREY , LIU ZHENG , KING DAVID
发明人： CHASTAGNOL FRANCK , ZHAO JIANLIANG , CHEN RUI , GOOD MATTHEW , SU YI-LING , WAID FREY , LIU ZHENG , KING DAVID
IPC分类号： H04K1/00
CPC分类号： G06Q30/06 , G06Q10/06 , G06Q30/0273
摘要： Content rights holders provide digital content to a hosting site to be used as reference content. The content owner specifies a policy for each digital content item, indicating how that content may be used on the site when uploaded by someone other than the content owner. An identification module compares the uploaded content against reference content. If the content matches reference content, the specified policy for that reference content is applied to the uploaded content. Policy options provided by the content owner include tracking the content to see how it is viewed, preventing the content from being distributed on the site, and allowing the content to be displayed in a revenue-sharing environment. In one embodiment, if the identification module matches the uploaded content to a reference item but the match does not have a sufficiently high level of confidence, the suggested match is queued for review by the content owner.
摘要翻译：内容权利持有者将数字内容提供给托管站点以用作参考内容。内容所有者为每个数字内容项目指定一个策略，指示当由内容所有者以外的人上传时，该内容可以在该网站上使用。识别模块将上传的内容与参考内容进行比较。如果内容与参考内容相匹配，则该引用内容的指定策略将应用于上传的内容。内容所有者提供的策略选项包括跟踪内容以查看其内容，以防止在网站上分发内容，并允许内容在收益分享环境中显示。在一个实施例中，如果识别模块将上传的内容与参考项匹配，但匹配没有足够高的置信度，则建议的匹配排队等待内容所有者审查。

6. 发明申请

WO2004053102A3 ANTIBODIES TO TREAT CANCER 审中-公开
标题翻译：治疗癌症的抗体
公开(公告)号：WO2004053102A3
公开(公告)日：2005-06-09
申请号：PCT/US0339771
申请日：2003-12-11
申请人： UNIV MASSACHUSETTS , CORIXA CORP , FANGER GARY , FANGER NEIL , KING DAVID , RETTER MARC W , ROCK KENNETH L
发明人： FANGER GARY , FANGER NEIL , KING DAVID , RETTER MARC W , ROCK KENNETH L
IPC分类号： C07K16/30 , A61K39/395 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/73 , C07K2317/732
摘要： Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.
摘要翻译：公开了用于治疗癌症，特别是黑素瘤，骨髓瘤，小细胞肺癌，胸腺淋巴瘤，T细胞淋巴瘤，B细胞淋巴瘤，骨肉瘤和急性T细胞白血病的组合物和方法。说明性组合物包括一种或多种编码这种抗神经节苷脂抗体的抗神经节苷脂抗体和多核苷酸。这些抗体可以是例如仓鼠抗体，嵌合人/仓鼠抗体或人源化抗体。所公开的组合物可用于例如治疗癌症并且可用于诱导癌细胞中的细胞凋亡。

7. 发明申请

WO2004094473A2 HUMANIZED ANTIBODIES TO INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) 审中-公开
标题翻译：干扰素ALPHA受体-1（IFNAR-1）的人源化抗体
公开(公告)号：WO2004094473A2
公开(公告)日：2004-11-04
申请号：PCT/US2004012649
申请日：2004-04-23
申请人： MEDAREX INC , CARDARELLI JOSEPHINE M , CHEN TSENG-HUI TIMOTHY , KING DAVID , BEBBINGTON CHRISTOPHER R , POGUE SARAH LEE , CARR FRANCIS J , WILLIAMS STEPHEN
发明人： CARDARELLI JOSEPHINE M , CHEN TSENG-HUI TIMOTHY , KING DAVID , BEBBINGTON CHRISTOPHER R , POGUE SARAH LEE , CARR FRANCIS J , WILLIAMS STEPHEN
IPC分类号： A61K39/395 , C07K16/28 , C07K16/44 , C07K16/46 , C07K16/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
摘要翻译：公开了结合IFNAR-1的人源化单克隆抗体以及相关的基于抗体的组合物和分子。还公开了包含人源化抗体和使用人源化抗体的治疗和诊断方法的药物组合物。

8. 发明申请

WO2009114130A3 PROCESS AND APPARATUS FOR DIAMOND SYNTHESIS 审中-公开
标题翻译：金刚石合成的工艺和装置
公开(公告)号：WO2009114130A3
公开(公告)日：2009-12-30
申请号：PCT/US2009001528
申请日：2009-03-10
申请人： UNIV MICHIGAN STATE , FRAUNHOFER USA , ASMUSSEN JES , GROTJOHN TIMOTHY , REINHARD DONNIE , RAMAMURTI RAHUL , YARAN M KAGAN , SCHUELKE THOMAS , BECKER MICHAEL , KING DAVID
发明人： ASMUSSEN JES , GROTJOHN TIMOTHY , REINHARD DONNIE , RAMAMURTI RAHUL , YARAN M KAGAN , SCHUELKE THOMAS , BECKER MICHAEL , KING DAVID
IPC分类号： C30B9/00 , C23C16/00 , C23C16/26
CPC分类号： C30B25/105 , C23C16/274 , C23C16/278 , C23C16/4585 , C23C16/4586 , C30B25/08 , C30B25/12 , C30B29/04 , H01J37/32192 , Y10T428/30
摘要： The present invention relates to a microwave plasma deposition process and apparatus for producing diamond, preferably as single crystal diamond (SCD). The process and apparatus enables the production of multiple layers of the diamond by the use of an extending device to increase the length and the volume of a recess in a holder containing a SCD substrate as layers of diamond are deposited. The diamond is used for abrasives, cutting tools, gems, electronic substrates, heat sinks, electrochemical electrodes, windows for high power radiation and electron beams, and detectors.
摘要翻译：本发明涉及微波等离子体沉积工艺和用于生产金刚石的装置，优选为单晶金刚石（SCD）。该方法和装置能够通过使用延伸装置来生产多层金刚石，以增加包含SCD衬底的保持器中的凹槽的长度和体积，因为沉积了金刚石层。金刚石用于磨料，切割工具，宝石，电子基板，散热片，电化学电极，大功率辐射窗和电子束以及探测器。

9. 发明申请

WO2005059106A3 INTERFERON ALPHA ANTIBODIES AND THEIR USES 审中-公开
标题翻译：干扰素ALPHA抗体及其用途
公开(公告)号：WO2005059106A3
公开(公告)日：2006-02-09
申请号：PCT/US2004041777
申请日：2004-12-10
申请人： MEDAREX INC , WITTE ALISON , WILLIAMS DENISE , CARDARELLI JOSEPHINE M , KING DAVID , PASSMORE DAVID
发明人： WITTE ALISON , WILLIAMS DENISE , CARDARELLI JOSEPHINE M , KING DAVID , PASSMORE DAVID
IPC分类号： C07K16/24 , C12N20060101 , A61K39/395
CPC分类号： C07K16/249 , A61K51/1021 , A61K2039/505 , C07K16/24 , C07K2317/21 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/76
摘要： The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
摘要翻译：本发明提供分离的抗干扰素α单克隆抗体，特别是人单克隆抗体，其抑制多种干扰素（IFN）α亚型的生物学活性，但基本上不抑制IFNα21的生物活性或IFNβ的生物学活性或IFNγ。还提供了免疫偶联物，双特异性分子和包含本发明抗体的药物组合物。本发明还提供了使用本发明的抗体抑制IFNα的生物学活性的方法，以及通过施用本发明的抗体来治疗由IFNα介导的疾病或病症的方法，例如自身免疫性疾病，移植排斥反应和移植物抗宿主病本发明的抗体。

10. 发明申请

WO2004093908A3 COMPOSITIONS AND METHODS FOR THE THERAPY OF INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译：炎症性皮肤疾病治疗的组合物和方法
公开(公告)号：WO2004093908A3
公开(公告)日：2005-06-02
申请号：PCT/US2004012651
申请日：2004-04-23
申请人： MEDAREX INC , PICKFORD LESLEY B , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T , KING DAVID
发明人： PICKFORD LESLEY B , BEBBINGTON CHRISTOPHER R , YARRANTON GEOFFREY T , KING DAVID
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2319/30
摘要： Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
摘要翻译：公开了用于治疗炎症性肠病（IBD）的组合物和方法，包括腹腔疾病，克罗恩病和溃疡性结肠炎。示例性组合物包含一种或多种抗1型干扰素拮抗剂，例如抗1型干扰素受体抗体拮抗剂及其片段，以及抑制1型干扰素与其受体（IFNAR）相互作用的多肽和小分子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式